DOI · e01.org

The taxane-based chemotherapy triplet is superior to the doublet in one to nine node-positive but not node-negative triple-negative breast cancer: results from a retrospective analysis

Sanxing Guo, Yonggang Shi, Shuo Lu, Yujie He, Guangyi Jin, Suzhi Zhang, Xingya Li · Journal of Cancer · 2020

  • DOI 10.7150/jca.44768
  • Publisher Ivyspring International Publisher
  • Type article
  • Issued 2020

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Journal of Cancer · Ivyspring International Publisher · article · 2020

Abstract

Background: Taxane-based regimens that are frequently used in adjuvant chemotherapy in early triple-negative breast cancer (TNBC) include a three-drug regimen (TAC and AC-T) and a two-drug regimen (TA and TC).Whether pathological lymph node stage guides taxane-based de-escalating chemotherapies in TNBC in adjuvant setting is still unclear.Methods: We retrospectively examined 381 patients with early TNBC over a median follow-up period of 75.9 months and compared the disease-free survival (DFS) and overall survival (OS) of patients who received adjuvant taxane-based three-drug chemotherapy and two-drug chemotherapy according to pathological lymph node stage (negative, pN0; 1-3 positive, pN1; 4-9 positive, pN2).Results: In 222 pN0 patients, the taxane-based three-drug regimen was not superior to the two-drug regimen.In 159 pN1-2 patients, the taxane-based three-drug regimen significantly improved DFS (5-year DFS rate, 78.2% vs.

46.9%;log-rank p=0.0002) and OS (5-year OS rate, 90.7% vs.

64.3%;log-rank p=0.0001) compared with the two-drug regimen.In a multivariable Cox regression analysis of pN1-2 patients, after adjustment for clinical characteristics, the taxane-based three-drug regimen significantly decreased the risk of recurrence (adjusted HR, 0.37; 95% CI, 0.22 to 0.64; p=0.0004) and death (adjusted HR, 0.22; 95% CI, 0.10 to 0.48; p=0.0001) compared with the two-drug regimen.Conclusions: The taxane-based chemotherapy triplet is superior to the chemotherapy doublet in patients with one to nine positive lymph nodes but not node-negative TNBC in adjuvant setting.These data suggest that pathological lymph node stage leads to de-escalating chemotherapy strategies in operable TNBC patients.

Open the resolved locator · 10.7150/jca.44768

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-19 20:13 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://www.jcancer.org/v11p6653.htm
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.